Kairos pharma, ltd. KAPA.US Overview
KAPA AI Analysis & Strategy
Browsing restrictions can be lifted for a fee.
KAPA Current Performance
-6.84%
Kairos pharma, ltd.
1.60%
Avg of Sector
0.32%
S&P500
KAPA Key Information
KAPA Revenue by Segments
Browsing restrictions can be lifted for a fee.
KAPA Net Income
Browsing restrictions can be lifted for a fee.
KAPA Cash Flow
Browsing restrictions can be lifted for a fee.
KAPA Profit Margin
Browsing restrictions can be lifted for a fee.
KAPA PE Ratio River
Browsing restrictions can be lifted for a fee.
KAPA Financial Forecast
Browsing restrictions can be lifted for a fee.
KAPA Earnings Table
Unit : USD
| QTR | Non-GAAP EPS | EPS YoY | EPS Surprise % | Sales | Sales YoY | Sales Surprise % | NPM |
|---|---|---|---|---|---|---|---|
| Current | |||||||
| 2024Q4 | |||||||
| 2024Q3 | |||||||
| 2024Q2 | |||||||
| 2024Q1 |
KAPA Profile
Kairos Pharma, Ltd. operates as a clinical-stage biopharmaceutical company that develops therapeutics for cancer patients. Its therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma. Kairos Pharma, Ltd. was formerly known as NanoGB13, Inc. and changed its name to Kairos Pharma, Ltd. in July 2016. The company was incorporated in 2013 and is based in Los Angeles, California.
Price of KAPA
KAPA FAQ
When is KAPA's latest earnings report released?
The most recent financial report for Kairos pharma, ltd. (KAPA) covers the period of 2025Q1 and was published on 2025/03/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating KAPA's short-term business performance and financial health. For the latest updates on KAPA's earnings releases, visit this page regularly.
How much cash does KAPA have?
At the end of the period, Kairos pharma, ltd. (KAPA) held Total Cash and Cash Equivalents of 3.62M, accounting for 0.46 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.
Is KAPA's EPS continuing to grow?
According to the past four quarterly reports, Kairos pharma, ltd. (KAPA)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -0.08. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.
What is the FCF of KAPA?
Kairos pharma, ltd. (KAPA)'s Free Cash Flow (FCF) for the period is -714K, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 2,083.33% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.